Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
What is known and objective: Esomeprazole, the S‐isomer of omeprazole, is a proton pump inhibitor which has been approved by over 125 countries, also known as NEXIUM®. Esomeprazole was developed to provide further improvement on efficacy for acid‐related diseases with higher systemic bioavailability...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 45; no. 5; pp. 1030 - 1039 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | equations & formulas research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Oct2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |